Sharemaestro Newsreel

MDxHealth SA Stock 12‑Month Price Target Cut to $2.2, Implies 376% Upside

MDxHealth SA's average stock price target has been reduced from $2.8 to $2.2 by analysts, with individual forecasts ranging from $1 to $4. This updated target suggests a potential upside of approximately 376% from its recent closing price. The consensus rating for the stock …

Spectral AI (MDAI): LMR funds report 6.2% beneficial stake via warrants

LMR-affiliated investment entities have reported a 6.2% beneficial ownership stake in Spectral AI, Inc. (MDAI) as of June 30, 2026. This ownership is primarily through warrants exercisable for 2,106,358 shares of Common Stock, with LMR Master Fund and LMR CCSA Master Fund each holding …

Earnings call transcript: PAVmed narrows Q2 2026 loss as shares slip

PAVmed Inc. (PAVM) reported a narrower GAAP net loss of $5.5 million, or $0.87 per share, in Q2 2026, down from $12.3 million a year earlier, driven by lower non-cash charges. Despite progress in its Lucid Diagnostics, Veris, PortIO, and Octeris programs, the stock …

Hims & Hers Health raises 2023 revenue outlook after strong Q2 growth despite margin drop

Werewolf Therapeutics Company Profile & Introduction

Bausch Health Stock Gains Momentum as Stronger Earnings, Raised Outlook and Debt Progress Lift Investor Optimism

Fresenius Medical Care stock steadies around $23 as investors weigh recent buybacks and guidance

Fresenius Medical Care stock is trading steadily around $23 in mid-August 2026, influenced by recent share buybacks and a modest year-to-date decline. The company's capital allocation strategy now includes renewed willingness for buybacks, alongside guidance for continued mid-single-digit revenue growth and improved operating income …

Armistice Capital (CALC) discloses 3.41M-share, 9.99% holding in CalciMedica

Armistice Capital, LLC and Steven Boyd have reported a significant holding in CalciMedica, Inc., disclosing beneficial ownership of 3,411,361 shares, which represents 9.99% of the company's common stock. The shares are directly held by Armistice Capital Master Fund Ltd., with Armistice Capital serving as …

Forte Biosciences earnings on deck as $2.2 billion argenx deal nears

Forte Biosciences is set to report its second-quarter earnings, which are expected to be largely a formality as the company awaits the completion of its $2.2 billion acquisition by argenx. Analysts anticipate a loss of $1.01 per share on zero revenue for Forte. The …

ARDX SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Ardelyx

SueWallSt has initiated an investigation into potential securities law violations by Ardelyx (NASDAQ: ARDX) following a significant drop in its stock price. The company lowered its 2026 IBSRELA revenue guidance by up to $80 million and withdrew its long-term XPHOZAH revenue target, citing payer …

Armistice Capital (BTAI) discloses 4.99% BioXcel Therapeutics stake via managed fund

Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership of 4.99% in BioXcel Therapeutics, Inc. (BTAI), amounting to 1,621,716 shares. These shares are held through Armistice Capital Master Fund Ltd., with Armistice Capital exercising shared voting and dispositive power as the investment …

Vertex Pharmaceuticals: I Was Wrong About Its Near-Term Prospects (Rating Upgrade)

Are Investors Undervaluing Tenet Healthcare (THC) Right Now?

Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in …

Trinity Biotech secures $7m from Perceptive Advisors By Investing.com

Trinity Biotech (NASDAQ:TRIB) has secured an additional $7.0 million investment from Perceptive Advisors, its largest financial investor, comprising $2.5 million in new debt and $4.5 million in capitalized interest. This funding will support the company's CGM+ continuous glucose monitoring platform, Trinovium subsidiary, and diagnostics …

Form 8K Lifeward Ltd. For: 14 August By Investing.com

This article reports on the filing of Form 8K by Lifeward Ltd. on August 14th. It appears to be a standard financial news brief from Investing.com, providing basic information about the filing and its publication details.

Quantum Biopharma Ltd. (CN:QNTM) Shares Decline as Biotech Uncertainty, Funding Risks and Clinical Development Challenges Pressure Investor Sentiment

Is Phase III Rezpegaldesleukin And Cash Runway Progress Altering The Investment Case For Nektar Therapeutics (NKTR)?

Why Did Oscar Health (OSCR) Fall After Record Profit and a Guidance Hike?

Oscar Health, Inc. (NYSE:OSCR) shares closed 11.9% lower at $26.54 on August 6, even after the insurer reported its most profitable first half and raised its full-year outlook. Second-quarter revenue rose 70% year over year to $4.88 billion, while the company swung to net …

Trinity Biotech Secures Additional $7.0 Million Investment from Perceptive Advisors and Regains Compliance with Nasdaq Minimum Bid Price Requirement

Trinity Biotech (NASDAQ: TRIB) has secured an additional $7.0 million investment from Perceptive Advisors, its largest financial investor, and has regained compliance with Nasdaq's minimum bid price requirement. The investment, consisting of new debt funding and capitalized interest, aims to bolster liquidity for strategic …

Trinity Biotech Regains Nasdaq Compliance After 10 Days at $1 or More

Canton Strategic Holdings (CNTN) posts $66.6M loss amid big Canton Coin bet

Embecta (EMBC) Q3 2026 Earnings Call Transcript

DOCS|Doximity Inc|Price:26.375|Chg%:-0.215

Tenet Healthcare Corporation (THC) Hits Fresh High: Is There Still Room to Run?

Shares of Tenet Healthcare (THC) have been strong performers lately, with the stock up 34.1% over the past month. The stock hit a new 52-week high of $270.57 in the previous session. Tenet has gained 34.4% since the start of the year compared to …

AMN Healthcare Services (NYSE:AMN) Stock Price Expected to Rise, Citizens Jmp Analyst Says

Is BioMarin Pharmaceutical (BMRN) Outperforming Other Medical Stocks This Year?

BioMarin Pharmaceutical (BMRN) is outperforming the Medical sector and its specific industry year-to-date, with a 15.3% return compared to the sector's 3%. The company holds a Zacks Rank #2 (Buy) due to improving analyst sentiment. Cardinal Health (CAH) is another medical stock showing strong …

Clover Health Is Proving Its Profit Model (NASDAQ:CLOV)

Crinetics Pharmaceuticals merger with Vertex Pharmaceuticals advances after regulatory clearances

The proposed merger between Crinetics Pharmaceuticals (NASDAQ:CRNX) and Vertex Pharmaceuticals (NASDAQ:VRTX) has progressed after securing regulatory clearances, including the expiration of the Hart-Scott-Rodino Antitrust Improvements Act waiting period and approvals in Austria, Germany, and Australia. The acquisition, valued at approximately $10 billion, is expected …

Equities Analysts Offer Predictions for CADL FY2028 Earnings

HC Wainwright Has Bullish Estimate for ACRV FY2030 Earnings

Attention Long-Term Shareholders of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY); Bloom Energy Corporation (NYSE: BE); Erasca, Inc. (NASDAQ: ERAS); and Insulet Corporation (NASDAQ: PODD): Grabar Law Office is Investigating Claims on Your Behalf

Grabar Law Office is investigating potential breaches of fiduciary duty by officers and directors of ARS Pharmaceuticals, Inc., Bloom Energy Corporation, Erasca, Inc., and Insulet Corporation. The investigations concern various allegations including misleading statements regarding product timelines, supply chain reliance, and manufacturing issues, which …

Canton Strategic's locking-as-a-service offering generated about $1.3M

Canton Strategic Holdings, Inc. Releases Second Quarter 2026 Financial and Operational Results

Is Galectin Therapeutics Inc (GALT) Overvalued After Q2 Earnings Miss? GF Score: 22/100

Capricor Therapeutics (CAPR) Stock Surges on FDA Application Ame

Brokers Offer Predictions for RAPP Q1 Earnings